Clinical Features and Treatment Differences Among Tuberculous, Brucellosis, and Pyogenic Spondylitis: A Cohort Study

结核性、布鲁氏菌性、化脓性脊柱炎的临床特征和治疗差异:一项队列研究

阅读:2

Abstract

PURPOSE: There was an increasing incidence of spinal infections. This study aimed to compare and contrast the clinical characteristics and treatment regimens for diverse types of spondylitis and to provide guidance for clinicians to make timely diagnosis and treatment. PATIENTS AND METHODS: One hundred and twenty-five patients with spinal infections admitted to the First Affiliated Hospital of Anhui Medical University from October 2019 to December 2024 were recruited. The patients were classified as having tuberculous spondylitis (TBS), brucellosis spondylitis (BS), or pyogenic spondylitis (PS). The patient's treatment regimen and course were dynamically followed up during hospitalization and after discharge. Comparisons of clinical characteristics and treatment among the three groups were performed by SPSS 26.0 and GraphPad Prism 10 statistical software. RESULTS: The proportion of male patients was greater than female patients (65.00% vs 35.00%). Fever accompanied by pain was more prevalent in the BS and PS groups than in the TBS group (P=0.003). Compared with the TBS and BS groups, the PS group had the shortest duration from symptom onset to hospitalization (P<0.001). Sepsis, invasive manipulation, elevated inflammatory markers, psoas abscesses, and the involvement of three or more vertebrae were significantly associated with the PS. In this study, the median duration of treatment was 77 weeks for TBS, 19 weeks for BS, and 13 weeks for PS. Adverse drug reactions (ADRs) should be monitored during treatment. Our results indicated that omadacycline and contezolid exhibited remarkable efficacy in the treatment of spinal infections. CONCLUSION: Patients of spinal infections with diverse etiologies presented varied clinical features and risk factors, the treatment should be individualized. Due to the long course of treatment, ADRs need to be monitored during treatment, and newer drugs such as omadacycline and contezolid are efficacious and have favorable safety profiles.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。